Biotech · Public company · South San Francisco, CA, US
Lyell Immunopharma, Inc.
Ticker LYEL · SEC CIK 0001806952
Track this companyFree. Adds Lyell Immunopharma, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials73 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline10
- axicabtagene ciloleucelPhase 3 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- lisocabtagene maraleucelPhase 3 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- rondecabtagene autoleucelPhase 3 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- CyclophosphamidePhase 2 · Relapsed Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- FludarabinePhase 2 · Relapsed Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- IMPT-514Phase 2 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
- LYL273Phase 2 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- Rondecabtagene autoleucel (ronde-cel)Phase 2 · Relapsed Non-Hodgkin LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- LYL797Phase 1 · Triple Negative Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- LYL845Phase 1 · MelanomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyPHASE3 · RECRUITING · started Jan 12, 2026ClinicalTrials.gov NCT07188558 · fetched Nov 12, 2026
- A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)PHASE1_PHASE2 · WITHDRAWN · started Feb 15, 2024ClinicalTrials.gov NCT06153095 · fetched Nov 12, 2026
- A Biomarker Screening Protocol for Participants With Solid TumorsTERMINATED · started May 19, 2023ClinicalTrials.gov NCT05891197 · fetched Nov 12, 2026
- Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell LymphomaPHASE1_PHASE2 · RECRUITING · started May 9, 2023ClinicalTrials.gov NCT05826535 · fetched Nov 12, 2026
- A Study to Investigate LYL845 in Adults With Solid TumorsPHASE1 · TERMINATED · started Dec 19, 2022ClinicalTrials.gov NCT05573035 · fetched Nov 12, 2026
- LYL273 for Patients With Relapsed or Refractory mCRCPHASE1_PHASE2 · RECRUITING · started Aug 1, 2022ClinicalTrials.gov NCT05319314 · fetched Nov 12, 2026
- A Study to Investigate LYL797 in Adults With Solid TumorsPHASE1 · TERMINATED · started Mar 29, 2022ClinicalTrials.gov NCT05274451 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Sep 10, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 6, 2026 · fetched Nov 12, 2026
- 10-K · 10-KSEC EDGAR · filed Mar 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 12, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 9, 2026 · fetched Nov 12, 2026